SteriPlas will be presented at the ISMCS 2023
Congratulations to Mr Thomas Schlöglhofer who has been invited to speak at the International Society for Mechanical Circulatory Support Scientific Congress (ISMCS) on Wednesday 1st November 2023.
His presentation, “Cold Atmospheric Plasma for Driveline Infection Treatment” will focus on the benefits of the SteriPlas for LVAD infections.
Our medical device has proven efficacy for the treatment of deep LVAD infections with the presence of biofilm. There is growing interest to use our SteriPlas Cold Plasma for LVAD infections due to its quick ability to destroy bacteria protected within biofilm deep within driveline cavity. This is regardless of the type of bacteria or its resistance profile. As LVAD infections can be healed in as quick as 1 week, it provides stability of the independent system and a better quality of life for patients with LVADs.
For more information about the SteriPlas, our clinical evidence or a free trial at your hospital contact us at info@adtecplasma
The Leader of Cold Plasma
There is expanding interest of our medical device for the treatment of chronic diabetic foot ulcers, deep sternal wounds and LVAD infections. We wish to remind you that if you are a Health Care Professional seeking to learn more about our medical device then please do get in contact with us. A member of our team will be able to show the full benefits and safety of using our medical device to treat these complicated conditions, with no side effects.
As Adtec Healthcare remains the leader of cold plasma medicine, we are lucky to be able to boast a wide clinical bibliography collection that really makes us stand out amongst the rest. We were the first company worldwide to do clinical trials of cold plasma on chronic wounds. Our clinical trials data has paved way in today’s medicine to show cold plasma as the go-to alternative for infection management.
If you are interested to bring the benefits of cold plasma to your patients, please email us at info@adtecplasma.com
How does the Adtec SteriPlas work so effectively?
Our patented cold plasma therapy utilises a physical mode of action approach delivered from an indirect microwave plasma source. Our cold argon plasma is an electrically charged and ionised gas that consists of charged particles, UV light and reactive oxygen and nitrogen species with the latter created as a by-product. They all work collectively to physically rupture the structure of bacteria even if they are protected within biofilm. Regardless of the type of bacteria, its resistance profile or whether they are Gram-positive or Gram-negative our cold plasma works quickly and effectively to destroy them. This has the leading advantage over conventional therapies such as antibiotics that rely on a chemical mode of action approach.
Although antibiotics have been a pivotal part of today’s medicine, they also contribute towards antimicrobial resistance rates particularly because bacteria can develop resistance such as those observed with diabetic foot ulcers that can often lead to amputations as a result.
However, as well as being fast-acting and effective, our cold plasma has shown that a primary or secondary resistance is unlikely to be developed due to its physical mode of action.
Mr Schlöglhofer to present SteriPlas at the ISHLT
Congratulations to Thomas Schlöglhofer from the Medical University of Vienna for his continued success of using our medical device to treat infections in LVAD patients. He will be presenting at The International Society for Heart and Lung Transplantation (ISHLT) conference in April to deliver the great results he has so far achieved.
His presentation, “Cold Atmospheric Plasma Therapy: A Powerful Tool for Treating Driveline Infections in Left Ventricular Assist Device Patients” will be during the “Bugs, Drugs, and Thugs: Fighting Infection in VADs Any Way We Can” Session on Wednesday 19th April between 5:30 PM - 6:30 PM.
We hope you will be there too to see him deliver his promising results.
For more information on how our medical device is fighting against multi resistant bacteria and biofilm in LVAD patients.
Poster presentation at the DFSG 2022
Did you see Dr Pierides' poster presentation yesterday at the DFSG Diabetic Foot Study Group conference? The poster featured the Adtec SteriPlas success in treating chronic infected diabetic foot ulcers.
The SteriPlas replaced the use of antibiotics for these heavily infected and impacted wounds and had shown remarkable success.
Adtec at the Diabetic Foot Study Group conference in Bratislava
Don't forget to visit us at the Diabetic Foot Study Group (DFSG) conference this weekend. We're having a great time welcoming you to our booth. Our SteriPlas is here ready to give you a live demonstration on how easy it is to use.
Presentation at the DFSG 2022
We're so excited for exhibiting at the Diabetic Foot Study Group (DFSG) conference next week. Please be sure to visit us at booth no.11 where we will based during the conference. We welcome you to see our SteriPlas Cold Plasma medical device live in action.
We're also excited to announce that the Diabetes Team at Kettering General Hospital NHS Foundation Trust will have a poster presentation illustrating the strong antibacterial efficacy and healing qualities of the Adtec SteriPlas for diabetic foot ulcers.
The poster, "DGH EXPERIENCE OF USING COLD PLASMA MEDICAL DEVICE AS AN ADJUNCT THERAPY TO ANTIMICROBIALS IN TREATING CHRONIC NON HEALING INFECTED DIABETIC FOOT ULCERS" will be presented by Jemma Cruickshank on Saturday 17th September, 13:25 - 14:25.
See you all soon!
The ISHLT discusses the Cold Plasma Project
We’re ecstatic to see our Adtec SteriPlas continue to raise awareness in the LVAD community. A great interview between the ISHLT and Mr Thomas Schlöglhofer from the Medical University of Vienna discussing the benefits of our cold atmospheric plasma medical device for the treatment of LVAD Infections and their broad study being conducted.
Thomas has been an avid user of our medical device for some time now collecting remarkable results with his LVAD patients, documenting the strong benefits of our medical device including the significant reduction of infection rates coupled with full healing, reduction of readmittance and the stabilisation of LVAD systems all with the added benefit of no side effects.
We look forward to the completion of this study and the publishing of the data which will be discussed at the ISHLT 2023 conference next year. We will also be exhibiting at this conference and excited to meet more people from the LVAD community.
https://youtu.be/6-L0sgXLx9o
Antimicrobial (antibiotic) Resistance – the drugs won’t work !
Antimicrobial resistance (AMR) poses a significant global threat of far-reaching proportions. It is estimated that drug resistant infections contribute to nearly 5 million deaths every year and predicted to increase to over 10 million deaths every year. WHO has declared that AMR is one of the top 10 global public health threats facing humanity.
(The worldwide total deaths from COVID is now just over 6 million and we all know how frightening it was before the vaccine was developed)
AMR occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines making infections harder to treat and increasing the risk of disease spread, severe illness and death. As a result, the medicines become ineffective and infections persist in the body, increasing the risk of spread to others. Microorganisms that develop antimicrobial resistance are sometimes referred to as “superbugs”. Without effective antimicrobials, the success of modern medicine in treating infections, including during major surgery and cancer chemotherapy, would be at increased risk. Chronic infections if left untreated could result in tissue damage, amputation, longer stays in hospitals, surgical interventions, or increased possibility of mortality. Patients who are infected with drug-resistant infections are more likely to develop complications and are up to three times more likely to die from the infection. Non-healing wounds in particular, are characterised by complex and mixed bacterial populations, often involving antibiotic-resistant bacteria as well as phenotypically tolerant bacteria in biofilm form. The biofilm factor is clearly of considerable clinical importance: it protects bacteria from antimicrobial agents leading to persistent and difficult to treat chronic infections, and it exacerbates the spread of antibiotic resistance. Surgical Site Infections are also linked to anti-microbial resistance.
SteriPlas cold plasma technology kills bacteria by a physical mode of action and bacteria are therefore unlikely to develop primary or secondary resistance, which we have documented from our clinical studies. SteriPlas cold plasma also kills antibiotic resistant bacteria (e.g. MRSA) and kills bacteria encased in biofilm which are typically up to 1000 times more resistant to antibiotics. SteriPlas has proven clinical efficacy in treating wound infections, diabetic foot infections and surgical site infections in all clinical studies, all with the bonus of no side effects reported.
SteriPlas cold plasma can be used to treat topical infections reserving antibiotics for severe systemic infections.
References
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext
https://www.worldometers.info/coronavirus/
https://www.who.int/health-topics/antimicrobial-resistance
https://healthfirsteurope.eu/wp-content/uploads/2020/11/A3A4-48pp-Booklet-Spreads-1.pdf
Bowler, P., Murphy, C. & Wolcott, R. Biofilm exacerbates antibiotic resistance: Is this a current oversight in antimicrobial stewardship?. Antimicrob Resist Infect Control 9, 162 (2020).
Diabetic Foot Study Group Conference
Are you excited as we are?
Looking forward to resuming exhibition season at the Diabetic Foot Study Group conference in Slovakia.
We'll be exhibiting between 16-18 Sept with our Adtec SteriPlas on demonstration ready to show you just how quick and effective it is to use and combat antibiotic resistant bacteria within diabetic foot ulcers.